Home

Glycosylation is the most common post-translational modification in the human proteome, with over half of all human proteins bearing covalently attached glycans. These glycan structures direct protein folding through ER quality control machinery, shield polypeptides from proteolytic degradation, regulate circulatory half-life via the asialoglycoprotein receptor, and serve as molecular signals for immune recognition and intracellular trafficking. For biopharmaceuticals, which constitute a rapidly growing share of approved drugs, glycan profiles are critical quality attributes that directly determine clinical efficacy and safety. Yet achieving the correct glycosylation on a therapeutic protein remains one of the field’s central challenges, as glycan biosynthesis is non-template-driven and highly sensitive to expression system and manufacturing conditions. This review connects the biological functions of glycosylation to the practical strategies of glycoengineering, examining how sequence design, expression system selection, and downstream enzymatic remodeling are used to optimize therapeutic glycoproteins. Clinical case studies spanning monoclonal antibodies, cytokines, and enzyme replacement therapies illustrate how glycan engineering translates into improved patient outcomes. We conclude by surveying emerging technologies poised to make precisely glycosylated therapeutics more accessible.

Despite significant advances in artificial intelligence (AI) algorithms for prostate cancer detection from whole slide images, the clinical applicability of these models remains limited. Variability in inter- and intrapathological grading, low generalizability of training datasets, and insufficient annotation precision restrict the performance of downstream models. This article introduces a novel Bayesian framework that addresses these challenges by generating pixel-wise posterior distributions, thereby providing a probabilistic output that enables the simulation of a panel consensus and enabling seamless integration of new data and models as they become available. The framework is demonstrated by integrating a Bayesian prior with a trained AI model to produce a per-pixel distribution of Gleason patterns. It is shown that using this distribution of Gleason patterns rather than a ground-truth label can improve model applicability, mitigate errors, and highlight areas of interest for pathologists. Furthermore, we present a high-quality, hand-curated dataset of prostate histopathological images annotated at the gland level by trained premedical students and verified by an expert pathologist. We highlight the potential of this adaptive and uncertainty-aware framework for developing clinically deployable AI tools that can support pathologists in accurate prostate cancer grading, improve diagnostic accuracy, and create positive patient outcomes. This work is presented as an early-stage, proof-of-concept study; the framework has not been validated for clinical use and is not intended for diagnostic deployment in its current form.

Artificial intelligence foundation models are increasingly deployed for prostate cancer Gleason grading, where GP3/GP4 distinction directly impacts treatment decisions (active surveillance vs. intervention). However, these models may achieve high validation accuracy by learning specimen-specific artifacts rather than generalizable biological features, limiting real-world clinical utility. We introduce PANDA-PLUS-Bench, a curated benchmark dataset derived from expertly annotated prostate biopsies designed specifically to quantify this failure mode. The benchmark comprises nine carefully selected whole slide images from nine unique patients containing diverse Gleason patterns, with non-overlapping tissue patches extracted at both 512 × 512 and 224 × 224-pixel resolutions across eight augmentation conditions. Using this benchmark, we evaluate seven foundation models (Virchow, Virchow2, UNI, UNI2, Phikon, Phikon-v2, and HistoEncoder) on their ability to separate biological signals from slide-level confounders. Our results reveal substantial variation in robustness across models: the Virchow models achieved the lowest slide-level encoding among large-scale models (slide ID accuracy: 80.7–81.0%), yet Virchow2 exhibited the lowest cross-slide accuracy (47.2%). HistoEncoder, trained specifically on prostate tissue, demonstrated the highest cross-slide accuracy (59.7%) and the strongest slide-level encoding (slide ID accuracy: 90.3%), suggesting tissue-specific training may enhance both biological feature capture and slide-specific signatures. All models exhibited measurable within-slide vs. cross-slide accuracy gaps, though the magnitude varied from 19.9 percentage points (HistoEncoder) to 26.9 percentage points (Phikon). We provide an open-source Google Colab notebook enabling researchers to evaluate additional foundation models against our benchmark using standardized metrics. PANDA-PLUS-Bench addresses a critical gap in foundation model evaluation by providing a purpose-built resource for robustness assessment in the clinically important context of Gleason grading.